|
Gender (female/male, n)
|
76/14
|
|
Age (mean ± SD, year)
|
33.1 ± 9.8
|
|
Disease duration (mean ± SD, days)
|
72.0 ± 53.0
|
|
SLEDAI (mean ± SD)
|
12.9 ± 7.9
|
|
Disease activity
| |
|
SLEDAI ≤ 8, (n, %)
|
40, (44.4)
|
|
SLEDAI > 8, (n, %)
|
50, (55.6)
|
|
Disease manifestations
| |
|
Arthritis (n, %)
|
41, (45.6)
|
|
Rash (n, %)
|
43, (47.8)
|
|
Oral ulcer (n, %)
|
11, (5.0)
|
|
Serositis (n, %)
|
16, (17.8)
|
|
Photosensitivity (n, %)
|
14, (15.6)
|
|
Raynaud’s phenomenon (n, %)
|
5, (5.6)
|
|
Hematological (n, %)
|
46, (51.1)
|
|
Lupus nephritis (proteinuria ≥ 0.5 g/24 h) (n, %)
|
21, (23.3)
|
|
Neuropsychiatric manifestations (n, %)
|
8, (8.9)
|
|
Autoantibody profile
| |
|
Anti-dsDNA + (n, %)
|
75, (83.3)
|
|
Anti-Sm + (n, %)
|
21, (23.3)
|
|
Anti-SSA + (n, %)
|
42, (46.7)
|
|
Anti-SSB + (n, %)
|
13, (14.4)
|
|
Anti-U1RNP + (n, %)
|
29, (32.2)
|
|
Anti-Rib-P + (n, %)
|
15, (16.7)
|
|
Anti-nucleosome-A + (n, %)
|
36, (40.0)
|
